User:Mr. Ibrahem/Opicapone

From Wikipedia, the free encyclopedia

Mr. Ibrahem/Opicapone
Clinical data
Trade namesOngentys
Other namesBIA 9-1067
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B2[1]
  • Not recommended
Routes of
administration		By mouth (capsules)
Drug classCatechol-O-methyltransferase (COMT) inhibitor[2]
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)[3]
  • US: ℞-only[4]
  • EU: Rx-only[2]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability~20%
Protein binding99.9%
MetabolismMainly sulfation, also reduction, glucuronidation, methylation
Elimination half-life0.7 to 3.2 hours
Duration of action>24 hours
ExcretionFeces (67%), urine (13%)
Identifiers
  • 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzene-1,2-diol
Chemical and physical data
FormulaC15H10Cl2N4O6
Molar mass413.17 g·mol−1
3D model (JSmol)
  • CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=NOC(=N2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-]
  • InChI=InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3
  • Key:ASOADIZOVZTJSR-UHFFFAOYSA-N

Opicapone, sold under the brand name Ongentys, is a medication used with levodopa/carbidopa for Parkinson's disease.[2][5] Specifically it is used for fluctuation in motor function before the next dose of levodopa.[6] Benefits are similar to entacapone.[5] It is taken by mouth.[2]

Common side effects include difficulty controlling movement (dyskinesia).[2] Other side effects may include constipation, low blood pressure, weight loss, and muscle breakdown.[5] It works by enhancing the effects of levodopa and thus dopamine in the parts of the brain that control movement and coordination.[2] It does this by blocks an enzyme involved in the breakdown of levodopa called catechol-O-methyltransferase (COMT).[2]

Opicapone was approved for medical use in Europe in 2016 and the United States in 2020.[2][5] In the United Kingdom a month of medication costs the NHS about £94 as of 2021.[6] This amount in the United States costs about 630 USD.[7]

References[edit]

  1. ^ "Archive copy" (PDF). Archived (PDF) from the original on 13 June 2021. Retrieved 13 June 2021.{{cite web}}: CS1 maint: archived copy as title (link)
  2. ^ a b c d e f g h i "Ongentys EPAR". European Medicines Agency. Archived from the original on 9 May 2020. Retrieved 28 April 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ^ "Ongentys 50 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 18 July 2019. Archived from the original on 4 June 2020. Retrieved 28 April 2020.
  4. ^ "Ongentys- opicapone capsule". DailyMed. 24 April 2020. Archived from the original on 25 October 2021. Retrieved 30 September 2020.
  5. ^ a b c d e f "Opicapone Monograph for Professionals". Drugs.com. Archived from the original on 22 June 2020. Retrieved 8 November 2021.
  6. ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 433. ISBN 978-0857114105.
  7. ^ "Ongentys Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 8 November 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Opicapone&oldid=1199108613"